TraderShifu

TraderShifu

Skye Bioscience (NASDAQ: SKYE) is gaining attention due to its lead obesity candidate, nimacimab, currently in Phase 2 trials with results expected in Q3/Q4 2025. Improved earnings and potential short-squeeze setup make this a high-reward opportunity. Why NASDAQ:SKYE is a Buy: Bullish Divergence: RSI shows higher lows while price makes lower lows. Stochastic...

TraderShifu

Probability Calculation for REKR Reaching $2 Estimated Probability: 75-80% Breakdown of Contributing Factors: 1. Technical Analysis Indicators (35-40%) Support Levels: The stock is currently trading near a significant support zone that has held in the past, increasing the likelihood of a bounce or upward movement. RSI Divergence: The presence of a...

TraderShifu

The Rollbit token (RLB) has recently formed a solid bottom, indicating a strong foundation for potential future gains. This price stabilization suggests that the token has found significant support, setting the stage for a bullish outlook. As the market sentiment shifts positively, we anticipate more upside potential in the near term. Investors and traders should...